Credit Suisse Group Reiterates “Hold” Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Ultragenyx Pharmaceutical (NASDAQ:RARE)‘s stock had its “hold” rating reaffirmed by stock analysts at Credit Suisse Group in a research report issued on Friday, AnalystRatings.com reports. They currently have a $64.00 price target on the biopharmaceutical company’s stock. Credit Suisse Group’s target price would indicate a potential downside of 18.12% from the stock’s current price.

Other equities analysts have also issued reports about the stock. Piper Sandler increased their price objective on shares of Ultragenyx Pharmaceutical from $70.00 to $83.00 and gave the company an “overweight” rating in a report on Tuesday, June 30th. Stifel Nicolaus increased their target price on shares of Ultragenyx Pharmaceutical from $70.00 to $82.00 and gave the stock a “buy” rating in a report on Monday, May 18th. Barclays increased their target price on shares of Ultragenyx Pharmaceutical from $87.00 to $99.00 and gave the stock an “overweight” rating in a report on Friday. Robert W. Baird increased their target price on shares of Ultragenyx Pharmaceutical from $75.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, July 1st. Finally, Wedbush increased their target price on shares of Ultragenyx Pharmaceutical from $83.00 to $91.00 and gave the stock an “outperform” rating in a report on Wednesday, July 1st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and fifteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $81.07.

NASDAQ RARE traded up $0.56 during trading hours on Friday, hitting $78.16. The company’s stock had a trading volume of 557,188 shares, compared to its average volume of 371,439. The stock has a fifty day moving average of $79.63 and a 200 day moving average of $63.43. Ultragenyx Pharmaceutical has a twelve month low of $31.99 and a twelve month high of $91.77. The company has a current ratio of 4.54, a quick ratio of 4.49 and a debt-to-equity ratio of 0.06.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($1.91) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.68) by ($0.23). Ultragenyx Pharmaceutical had a negative net margin of 188.51% and a negative return on equity of 56.80%. The business had revenue of $36.31 million during the quarter, compared to analyst estimates of $36.74 million. During the same quarter in the prior year, the company earned ($1.82) earnings per share. The company’s quarterly revenue was up 99.8% on a year-over-year basis. On average, analysts predict that Ultragenyx Pharmaceutical will post -6.38 EPS for the current year.

In other news, Director Matthew K. Fust sold 1,875 shares of the stock in a transaction on Monday, May 18th. The shares were sold at an average price of $75.00, for a total transaction of $140,625.00. Following the completion of the sale, the director now owns 55,424 shares of the company’s stock, valued at $4,156,800. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Emil D. Kakkis sold 40,000 shares of the stock in a transaction on Monday, July 13th. The stock was sold at an average price of $85.35, for a total transaction of $3,414,000.00. The disclosure for this sale can be found here. Insiders have sold 81,110 shares of company stock valued at $6,667,359 in the last three months. 8.20% of the stock is owned by insiders.

Institutional investors have recently added to or reduced their stakes in the stock. Parametric Portfolio Associates LLC grew its position in Ultragenyx Pharmaceutical by 17.0% in the first quarter. Parametric Portfolio Associates LLC now owns 33,151 shares of the biopharmaceutical company’s stock valued at $1,473,000 after purchasing an additional 4,818 shares in the last quarter. State Street Corp grew its position in Ultragenyx Pharmaceutical by 1.4% in the first quarter. State Street Corp now owns 2,229,351 shares of the biopharmaceutical company’s stock valued at $99,050,000 after purchasing an additional 30,604 shares in the last quarter. Man Group plc grew its position in Ultragenyx Pharmaceutical by 87.2% in the fourth quarter. Man Group plc now owns 96,143 shares of the biopharmaceutical company’s stock valued at $4,107,000 after purchasing an additional 44,797 shares in the last quarter. Franklin Resources Inc. grew its position in Ultragenyx Pharmaceutical by 3.2% in the first quarter. Franklin Resources Inc. now owns 382,473 shares of the biopharmaceutical company’s stock valued at $16,993,000 after purchasing an additional 11,823 shares in the last quarter. Finally, Nuveen Asset Management LLC grew its position in Ultragenyx Pharmaceutical by 9.4% in the first quarter. Nuveen Asset Management LLC now owns 331,091 shares of the biopharmaceutical company’s stock valued at $14,710,000 after purchasing an additional 28,322 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

Recommended Story: What is a Stop Order?

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.